Graphical assessment of consistency in treatment effect among countries in multi-regional clinical trials

Author:

Chen Joshua1,Zheng Hao2,Quan Hui3,Li Gang4,Gallo Paul5,Ouyang Soo Peter6,Binkowitz Bruce1,Ting Naitee7,Tanaka Yoko8,Luo Xiaolong6,Ibia Ekopimo9,

Affiliation:

1. Merck Research Laboratories, Rahway, NJ, USA

2. Department of Statistics, University of Wisconsin-Madison, Madison, WI, USA

3. Sanofi, Bridgewater, NJ, USA

4. Johnson & Johnson, Raritan, NJ, USA

5. Novartis, East Hanover, NJ, USA

6. Celgene, Summit, NJ, USA

7. Boehringer Ingelheim, Ridgefield, CT, USA

8. Eli Lilly, Indianapolis, IN, USA

9. Merck Research Laboratories, Washington, DC, USA

Abstract

Background One key objective of a multi-regional clinical trial (MRCT) is to use the trial results to ‘bridge’ from the global level to local region in support of local registrations. However, data from each individual country are typically limited and the large number of countries will increase the chance of false positive findings. Purpose Graphical tools to facilitate identification of potential outlying countries could be useful for country-level assessment. Existing methods such as funnel plot and expected range of treatment effect can substantially increase the false positive rate. The expected range approach can also have a very low power when there are a large number of small countries, which is typical in a MRCT. Methods In this article, we apply normal probability plots, commonly used as a diagnostic tool in linear regression analysis, to assess the differences among countries. Evidence of possible inconsistency, which incorporates both the estimated treatment effect and sample size, is plotted against its expected order statistic. Results A simulation study is conducted to assess the impact of the negative correlation among residuals due to unequal sample sizes among countries and the performance of the proposed methods compared to existing approaches. The proposed methods tend to have a balanced consideration with substantially smaller false positive rate and reasonable probability to identify outlying countries in realistic scenarios. Limitations While much lower than that of commonly used methods, the false positive rates of the proposed methods are not strictly controlled. This may be acceptable for these graphical tools with intention to flag potential outliers for investigation. Conclusions We recommend routine use of normal probability plots in MRCTs as a tool to identify potential outliers. If the normal probability plot is approximately linear but has heavy tails with a few outlying countries, these potential outliers should be examined carefully to understand the possible reasons.

Publisher

SAGE Publications

Subject

Pharmacology,General Medicine

Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3